ProShare Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

ProShare Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11,127	Closed	-$42.6K	–	2010
2025 Q2	$42.6K	Buy	11,127 +343	+3%	+$887	﹤0.01%	2011
2025 Q1	$62K	Sell	10,784 -3,247	-23%	-$19.2K	﹤0.01%	1924
2024 Q4	$70K	Buy	+14,031	New	+$72K	﹤0.01%	2132
2022 Q1	–	Sell	-10,602	Closed	-$43K	–	2200
2021 Q4	$43K	Buy	+10,602	New	+$80.9K	﹤0.01%	2300
2021 Q3	–	Sell	-12,591	Closed	-$143K	–	2013
2021 Q2	$143K	Buy	+12,591	New	+$151K	﹤0.01%	2228

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

ProShare Advisors's ALDX Position: Q3 2025 in Review

ProShare Advisors sold out of Aldeyra Therapeutics (ALDX) in Q3 2025, closing a stake of 11,127 shares — an estimated $42.6K sold.

ProShare Advisors first reported a position in ALDX in Q2 2021 and held it in 5 quarters. The position peaked at $143K in Q2 2021. 130 funds tracked by Wall St. Rank hold ALDX as of Q3 2025.

ProShare Advisors reported no remaining Aldeyra Therapeutics position as of Q3 2025 after selling out during the quarter.
ProShare Advisors sold 11,127 Aldeyra Therapeutics shares in Q3 2025, an estimated $42.6K.
ProShare Advisors first reported a position in Aldeyra Therapeutics in Q2 2021 and held it in 5 quarters.
ProShare Advisors's Aldeyra Therapeutics position peaked at $143K in Q2 2021.
130 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2025.

Based on ProShare Advisors's 13F filing for Q3 2025, filed 6 Nov 2025.